Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution
Gland Pharma Limited (Gland or Company), a generic injectable-focused pharmaceutical company, has received tentative approval from the United States Food and Drug Administration (USFDA) for Latanoprostene Bunod Ophthalmic Solution, 0.024%. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vyzulta® Ophthalmic Solution,